Kalbe Farma Tbk PT
IDX:KLBF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
IDX:KLBF
Watchlist
Price: 1 315 IDR 2.33%
Market Cap: 61.6T IDR
Have any thoughts about
Kalbe Farma Tbk PT?
Write Note

Relative Value

The Relative Value of one KLBF stock under the Base Case scenario is 1 884.68 IDR. Compared to the current market price of 1 315 IDR, Kalbe Farma Tbk PT is Undervalued by 30%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KLBF Relative Value
Base Case
1 884.68 IDR
Undervaluation 30%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
98
vs Industry
46
Median 3Y
2.7
Median 5Y
2.7
Industry
2.5
Forward
2
vs History
82
vs Industry
19
Median 3Y
24.7
Median 5Y
24.6
Industry
21.8
Forward
18.3
vs History
98
vs Industry
23
Median 3Y
27.3
Median 5Y
22.3
Industry
16.1
vs History
93
vs Industry
16
Median 3Y
55.1
Median 5Y
39.7
Industry
23.8
vs History
92
vs Industry
24
Median 3Y
3.8
Median 5Y
3.8
Industry
2.1
vs History
98
vs Industry
47
Median 3Y
2.5
Median 5Y
2.6
Industry
2.7
Forward
1.9
vs History
93
vs Industry
35
Median 3Y
6.3
Median 5Y
6.2
Industry
5.2
vs History
79
vs Industry
20
Median 3Y
18.5
Median 5Y
17.5
Industry
13.5
Forward
11.6
vs History
79
vs Industry
23
Median 3Y
18.5
Median 5Y
17.5
Industry
16.8
Forward
13.5
vs History
98
vs Industry
24
Median 3Y
25.1
Median 5Y
21.4
Industry
15.2
vs History
98
vs Industry
16
Median 3Y
38.7
Median 5Y
37.9
Industry
19.3
vs History
92
vs Industry
27
Median 3Y
3.7
Median 5Y
3.7
Industry
1.9

Multiples Across Competitors

KLBF Competitors Multiples
Kalbe Farma Tbk PT Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ID
Kalbe Farma Tbk PT
IDX:KLBF
60.7T IDR 1.9 19.7 14.4 14.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.3B USD 18.5 90.4 48.5 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
349.7B USD 4 23.8 11.5 15
US
Merck & Co Inc
NYSE:MRK
251.6B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
199.5B CHF 3.4 17.3 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.6B GBP 4.1 31.4 168.9 253.1
CH
Novartis AG
SIX:NOVN
171.3B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.4B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average P/S: 382 942.1
1.9
27%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average P/E: 31
19.7
44%
0.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.4
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.8
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.3
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average EV/EBITDA: 415
14.4
60%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
168.9
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average EV/EBIT: 1 811.5
14.4
39%
0.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.1
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Discover More
Back to Top